CSF2 and neoplasm: Given the anti-tumorigenic activity of Ova-IC-nAPCs generated in vitro in the presence of GM-CSF (see Fig. 4d) and the success of anti-tumor strategies involving GM-CSF68–72, we combined a single dose of 3G8-fOva with sequential doses of GM-CSF.